This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chiang, F.-Y.
Right arrow Articles by Climo, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chiang, F.-Y.
Right arrow Articles by Climo, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Antibiotics
*MRSA
*Staphylococcal Infections
Hazardous Substances DB
*VANCOMYCIN

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2003, p. 3002-3004, Vol. 47, No. 9
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.9.3002-3004.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Efficacy of Linezolid Alone or in Combination with Vancomycin for Treatment of Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus

Fu-Yu Chiang1 and Michael Climo1,2*

Division of Infectious Disease, Virginia Commonwealth University Health Systemthe,1 Hunter Holmes McGuire Veteran Affairs Medical Center, Richmond, Virginia2

Received 15 January 2003/ Returned for modification 17 May 2003/ Accepted 9 June 2003

The levels of effectiveness of linezolid, vancomycin, and the combination of linezolid and vancomycin were compared in the rabbit model of endocarditis caused by a clinical methicillin-resistant Staphylococcus aureus (MRSA) isolate. Vancomycin alone was more effective than either linezolid alone or the combination of linezolid and vancomycin for the treatment of endocarditis due to MRSA.

* Corresponding author. Mailing address: Hunter Holmes McGuire Veteran Affairs Medical Center, 1201 Broad Rock Blvd., Section 111-C, Richmond, VA 23249. Phone: (804) 675-5018. Fax: (804) 675-5437. E-mail: Michael.Climo{at}med.va.gov.

Antimicrobial Agents and Chemotherapy, September 2003, p. 3002-3004, Vol. 47, No. 9
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.9.3002-3004.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Nguyen, H. M., Graber, C. J. (2009). Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?. J Antimicrob Chemother 0: dkp377v1-dkp377 [Abstract] [Full Text]  
  • Singh, S. R., Bacon, A. E. III, Young, D. C., Couch, K. A. (2009). In Vitro 24-Hour Time-Kill Studies of Vancomycin and Linezolid in Combination versus Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 4495-4497 [Abstract] [Full Text]  
  • Tsaganos, T., Skiadas, I., Koutoukas, P., Adamis, T., Baxevanos, N., Tzepi, I., Pelekanou, A., Giamarellos-Bourboulis, E. J., Giamarellou, H., Kanellakopoulou, K. (2008). Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis. J Antimicrob Chemother 62: 381-383 [Abstract] [Full Text]  
  • Chi, C.-Y., Lauderdale, T.-L., Wang, S.-M., Wu, J.-M., Yang, Y.-J., Liu, C.-C. (2008). Health Care-Associated Endocarditis Caused by Staphylococcus aureus with Reduced Susceptibility to Vancomycin. J. Clin. Microbiol. 46: 810-813 [Abstract] [Full Text]  
  • Fox, P. M., Lampen, R. J., Stumpf, K. S., Archer, G. L., Climo, M. W. (2006). Successful Therapy of Experimental Endocarditis Caused by Vancomycin-Resistant Staphylococcus aureus with a Combination of Vancomycin and {beta}-Lactam Antibiotics.. Antimicrob. Agents Chemother. 50: 2951-2956 [Abstract] [Full Text]  
  • Falagas, M. E., Manta, K. G., Ntziora, F., Vardakas, K. Z. (2006). Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother 58: 273-280 [Abstract] [Full Text]  
  • Jacqueline, C., Caillon, J., Grossi, O., Le Mabecque, V., Miegeville, A.-F., Bugnon, D., Batard, E., Potel, G. (2006). In Vitro and In Vivo Assessment of Linezolid Combined with Ertapenem: a Highly Synergistic Combination against Methicillin-Resistant Staphylococcus aureus.. Antimicrob. Agents Chemother. 50: 2547-2549 [Abstract] [Full Text]  
  • Athanassopoulos, G., Pefanis, A., Sakka, V., Iliopoulos, D., Perrea, D., Giamarellou, H. (2006). Linezolid in Prophylaxis against Experimental Aortic Valve Endocarditis Due to Streptococcus oralis or Enterococcus faecalis. Antimicrob. Agents Chemother. 50: 654-657 [Abstract] [Full Text]  
  • Jones, R. N., Ross, J. E., Fritsche, T. R., Sader, H. S. (2006). Oxazolidinone susceptibility patterns in 2004: report from the Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 57: 279-287 [Abstract] [Full Text]  
  • Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G. Jr, Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., Tong, D. C., Steckelberg, J. M., Baltimore, R. S., Shulman, S. T., Burns, J. C., Falace, D. A., Newburger, J. W., Pallasch, T. J., Takahashi, M., Taubert, K. A. (2005). Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America. Circulation 111: e394-e434 [Abstract] [Full Text]  
  • Jacqueline, C., Navas, D., Batard, E., Miegeville, A.-F., Le Mabecque, V., Kergueris, M.-F., Bugnon, D., Potel, G., Caillon, J. (2005). In Vitro and In Vivo Synergistic Activities of Linezolid Combined with Subinhibitory Concentrations of Imipenem against Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49: 45-51 [Abstract] [Full Text]  
  • LaPlante, K. L., Rybak, M. J. (2004). Impact of High-Inoculum Staphylococcus aureus on the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 48: 4665-4672 [Abstract] [Full Text]  
  • Patel, M. V., De Souza, N. J., Gupte, S. V., Jafri, M. A., Bhagwat, S. S., Chugh, Y., Khorakiwala, H. F., Jacobs, M. R., Appelbaum, P. C. (2004). Antistaphylococcal Activity of WCK 771, a Tricyclic Fluoroquinolone, in Animal Infection Models. Antimicrob. Agents Chemother. 48: 4754-4761 [Abstract] [Full Text]  
  • Krueger, W. A., Kottler, B., Will, B. E., Heininger, A., Guggenberger, H., Unertl, K. E. (2004). Treatment of Meningitis Due to Methicillin-Resistant Staphylococcus epidermidis with Linezolid. J. Clin. Microbiol. 42: 929-932 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»